At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 23, 2026 at 16:05 ET
IDEAYA Biosciences filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders, where all three proposals passed: election of three Class I directors, ratification of PricewaterhouseCoopers as auditor, and advisory approval of executive compensation. Separately, the Board elected CEO Yujiro S. Hata as Chairman and Terry Rosen as Lead Independent Director. This is a routine governance filing with no material financial or operational impact.
- Annual Meeting held June 16, 2026; all three proposals passed.
- Directors elected: Yujiro S. Hata (70.5M for), M. Garret Hampton (56.7M for), Catherine J. Mackey (70.3M for).
- Ratification of PwC as auditor: 82.6M for, 141K against.
- Advisory vote on executive compensation: 64.3M for, 8.3M against.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access